Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease

European Journal of Haematology

Volumn 78, Issue 4, 2007, Pages 358-360

  Makinson, Alain ^a   Martelli, Nicolas ^b   Peyrière, Hélène ^b   Turriere, Chrystell ^a   Moing, Vincent Le ^a   Reynes, Jacques ^a  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b LAPEYRONIE HOSPITAL   (France)

Author keywords

Drug interaction; Lopinavir ritonavir; Neutropenia; Vinblastine

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; CLINDAMYCIN; DACARBAZINE; DOXORUBICIN; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PENTAMIDINE; PERINDOPRIL; PREDNISOLONE; PYRIMETHAMINE; RAZOXANE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SPIRONOLACTONE; TENOFOVIR; VINBLASTINE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER THERAPY; CARDIOMYOPATHY; CASE REPORT; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEBRILE NEUTROPENIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEUTROPENIA; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; MALE; NEUTROPENIA; REMISSION INDUCTION; TREATMENT OUTCOME; VINBLASTINE;

EID: 33847630339     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00827.x     Document Type: Article

References (6)

1. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002;100:1984-8.
2. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicine, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001;91:155-63.
3. Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004;104:2943- 6.
4. Kotb R, Vincent I, Dulioust A, et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol 2006;76:269-71.
5. Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicine in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol 2004;15:1805-9.
6. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999;57:1147- 52.